Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cellbxhealth PLC (ANPCF)
Guildford, GB
CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +93.20% | +45.15% | +18.45% | +18.45% | -87.64% | -96.17% | -98.18% | -98.30% | -98.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Diagnostics & Research: +7.9%-52.8% Q4'25: -39.3% (vs Q3'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%-14.3% Q4'25: +10.9% (vs Q3'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-973.1% Q4'25: -858.4% (vs Q3'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-1,495.6% Q4'25: -1,896.9% (vs Q3'24)
-
ROIC Medical - Diagnostics & Research: +5.2%-1,214.2% Q4'25: -2,530.8% (vs Q3'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+20.0% Q4'25: +252.1% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.12× Q4'25: -0.08× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
801.0K
est: 478.5K (+67.4%)
|
—
est: 337.0K (-100.0%)
|
361.0K
est: 1.27M (-71.7%)
|
498.0K
est: 726.7K (-31.5%)
|
628.0K
est: 679.2K (-7.5%)
|
678.0K
est: 1.55M (-56.2%)
|
871.5K
est: 1.55M (-43.7%)
|
762.0K
est: 602.4K (+26.5%)
|
1.01M
est: 1.00M (+1.1%)
|
1.04M
est: 1.05M (-0.7%)
|
2.19M
est: 2.10M (+4.3%)
|
2.86M
est: 2.90M (-1.3%)
|
1.35M
est: 1.40M (-3.5%)
|
2.09M
202.6K – 3.97M
+49.2% YoY
|
5.57M
540.3K – 10.60M
+166.7% YoY
|
8.26M
800.8K – 15.71M
+48.2% YoY
|
| EBITDA |
-2.15M
est: -478.5K (-350.2%)
|
-3.67M
est: -337.0K (-990.0%)
|
-5.04M
est: -1.27M (-295.5%)
|
-6.90M
est: -726.7K (-849.2%)
|
-8.14M
est: -679.2K (-1,097.8%)
|
-9.83M
est: -1.55M (-534.7%)
|
-11.29M
est: -1.55M (-629.6%)
|
-12.23M
est: -602.4K (-1,930.8%)
|
-15.72M
est: -1.00M (-1,468.7%)
|
-24.39M
est: -1.05M (-2,225.5%)
|
-19.00M
est: -2.10M (-806.5%)
|
-13.02M
est: -2.90M (-349.2%)
|
-14.58M
est: -1.40M (-941.6%)
|
-2.09M
-3.97M – -202.6K
-49.2% YoY
|
-5.57M
-10.60M – -540.3K
-166.7% YoY
|
-8.26M
-15.71M – -800.8K
-48.2% YoY
|
| EBIT |
-2.20M
est: -478.5K (-359.4%)
|
-3.78M
est: -337.0K (-1,023.0%)
|
-5.43M
est: -1.27M (-325.7%)
|
-7.41M
est: -726.7K (-919.6%)
|
-8.93M
est: -679.2K (-1,214.1%)
|
-10.87M
est: -1.55M (-602.3%)
|
-12.63M
est: -1.55M (-716.0%)
|
-13.65M
est: -602.4K (-2,166.4%)
|
-17.21M
est: -1.00M (-1,617.1%)
|
-25.49M
est: -1.05M (-2,330.2%)
|
-21.31M
est: -2.10M (-916.6%)
|
-14.72M
est: -2.90M (-407.8%)
|
-20.20M
est: -1.40M (-1,343.2%)
|
-2.09M
-3.97M – -202.6K
-49.2% YoY
|
-5.57M
-10.60M – -540.3K
-166.7% YoY
|
-8.26M
-15.71M – -800.8K
-48.2% YoY
|
| Net Income |
-1.06M
est: -8.45M (+87.4%)
|
-3.59M
est: -24.76M (+85.5%)
|
-4.89M
est: -33.20M (+85.3%)
|
-6.57M
est: -22.93M (+71.4%)
|
-7.56M
est: -17.71M (+57.3%)
|
-8.94M
est: -20.05M (+55.4%)
|
-11.33M
est: -20.05M (+43.5%)
|
-11.61M
est: -17.15M (+32.3%)
|
-15.01M
est: -20.74M (+27.6%)
|
-21.69M
est: -26.58M (+18.4%)
|
-20.13M
est: -22.43M (+10.2%)
|
-14.23M
est: -16.70M (+14.8%)
|
-19.51M
est: -20.27M (+3.8%)
|
-1.62M
-3.52M – 281.5K
+92.0% YoY
|
-985.4K
-2.14M – 171.4K
+39.1% YoY
|
-211.2K
-459.0K – 36.7K
+78.6% YoY
|
| SGA |
188.0K
est: 162.2K (+15.9%)
|
3.78M
est: 114.2K (+3,213.4%)
|
60.0K
est: 432.1K (-86.1%)
|
125.0K
est: 246.3K (-49.3%)
|
400.0K
est: 230.2K (+73.8%)
|
236.0K
est: 524.6K (-55.0%)
|
3.47M
est: 524.6K (+560.5%)
|
372.0K
est: 204.2K (+82.2%)
|
342.0K
est: 339.6K (+0.7%)
|
557.0K
est: 355.4K (+56.7%)
|
382.0K
est: 710.3K (-46.2%)
|
455.0K
est: 7.32M (-93.8%)
|
15.41M
est: 3.53M (+336.4%)
|
5.27M
511.2K – 10.03M
+49.2% YoY
|
14.05M
1.36M – 26.74M
+166.7% YoY
|
20.83M
2.02M – 39.64M
+48.2% YoY
|
| EPS |
-0.02
est: -0.03 (+17.7%)
|
-0.08
est: -0.08 (+10.1%)
|
-0.08
est: -0.11 (+26.2%)
|
-0.09
est: -0.08 (-15.1%)
|
-0.08
est: -0.06 (-31.7%)
|
-0.07
est: -0.07 (+3.5%)
|
-0.07
est: -0.07 (-1.6%)
|
-0.07
est: -0.06 (-12.1%)
|
-0.07
est: -0.07 (+5.2%)
|
-0.09
est: -0.09 (+2.5%)
|
-0.08
est: -0.08 (-1.7%)
|
-0.05
est: -0.05 (-2.1%)
|
-0.06
est: -0.06 (+3.8%)
|
0.00
-0.01 – 0.00
+92.0% YoY
|
0.00
-0.01 – 0.00
+39.1% YoY
|
0.00
0.00 – 0.00
+78.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cristina Ciccioli | Head of Assay Development | — | — |
| Lauren Arthy-Miles | ESG Lead | — | — |
| Michelle Munson | Chief of Staff | — | female |
| Peter Michael Collins | CEO & Director | — | male |
| Sinéad Eithne Armstrong | Finance Director & Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANPCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
